Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.72 |
| ▸ | HTR2A | P28223 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 6/20 | 0.72 |
| ▸ | HTR2C | P28335 | 5/20 | 0.72 |
| ▸ | HTR2B | P41595 | 5/20 | 0.72 |
| ▸ | DRD4 | P21917 | 4/20 | 0.72 |
| ▸ | DRD2 | P14416 | 4/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | DRD1 | P21728 | 3/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.72 |
| ▸ | HTR1D | P28221 | 3/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.72 |
| ▸ | HRH1 | P35367 | 3/20 | 0.72 |
| ▸ | HTR3A | P46098 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL23326358 | 0.85 | DRD3 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL18020 | 0.85 | DRD3 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL9122085 | 0.85 | DRD3 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL29356897 | 0.85 | DRD3 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL353397 | 0.85 | DRD3 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL340474 | 0.83 | MEN1 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL9752060 | 0.83 | DRD3 (0.97) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL8344416 | 0.83 | DRD3 (0.97) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL29366576 | 0.83 | MEN1 (1.00) | DRD3HTR2AHTR1AHTR2CHTR2B | |
| Mianserin SCHEMBL11336834 | 0.83 | HTR2A (0.97) | DRD3HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20200352863-A1 | Methods For Administering Weight Loss Medications | Naipropion Pharmaceuticals LLC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20190282503-A1 | Methods For Administering Weight Loss Medications | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2019-09-19 | — | — | US | disclosed |
| US-10307376-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180360760-A1 | Methods For Administering Weight Loss Medications | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2018-12-20 | — | — | US | disclosed |
| US-20160338965-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2016-11-24 | — | — | US | disclosed |
| US-20160193152-A1 | METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | NALPROPION PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9125868-B2 | Methods for administering weight loss medications | OREXIGEN THERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150164806-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | VALORBEC SOCIETE EN COMMANDITE (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20140322318-A1 | METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | OREXIGEN THERAPEUTICS, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20070185084-A1 | COMPOSITIONS OF AN ANTICONVULSANT AND METHODS OF USING THE SAME FOR REVERSING WEIGHT GAIN | OREXIGEN THERAPEUTICS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007084290-A2 | COMPOSITIONS OF AN ANTICONVULSANT AND PSYCHOTHERAPEUTIC AND METHODS OF USING THE SAME FOR REVERSING WEIGHT GAIN | OREXIGEN THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1909903-A | Anticonvulsant and antipsychotic combinations for affecting weight loss | UNIV DUKE (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1734955-A2 | COMPOSITIONS OF AN ANTICONVULSANT AND AN ANTIPSYCHOTIC DRUG FOR AFFECTING WEIGT LOSS | Duke University (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006130522-A2 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | OREXIGEN THERAPEUTICS, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276412-A1 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-12-07 | — | — | US | disclosed |
| US-20060160750-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | DUKE UNIVERSITY | 2006-07-20 | — | — | US | disclosed |
| US-20060079501-A1 | Compositions of an anticonvulsant and mirtazapine to prevent weight gain | DUKE UNIVERSITY | 2006-04-13 | — | — | US | disclosed |
| US-20050181070-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2005-08-18 | — | — | US | disclosed |
| WO-2005070461-A2 | COMPOSITIONS OF AN ANTICONVULSANT AND AN ANTIPSYCHOTIC DRUG FOR AFFECTING WEIGHT LOSS | DUKE UNIVERSITY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181070-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | GAP43, PYGB, GPR119 | DRD3 517/4885HTR2A 186/4885HTR1A 238/4885 |
| US-20070185084-A1 | COMPOSITIONS OF AN ANTICONVULSANT AND METHODS OF USING THE SAME FOR REVERSING WEIGHT GAIN | GAP43, PYGB, CHAT | DRD3 1891/4885HTR2A 688/4885HTR1A 580/4885 |
| US-20060276412-A1 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | GRIN2A, GRIN2D, GRIN2B | DRD3 286/4885HTR2A 28/4885HTR1A 35/4885 |
| US-20060160750-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | GAP43, PYGB, GPR119 | DRD3 517/4885HTR2A 186/4885HTR1A 238/4885 |
| US-20060079501-A1 | Compositions of an anticonvulsant and mirtazapine to prevent weight gain | RIMKLA, CPT1B, SLC6A11 | DRD3 681/4885HTR2A 646/4885HTR1A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.